Dr. Reddy's Laboratories Ltd. 500124 shares advanced 2.39% to 1,303.00 Indian rupees Wednesday, on what proved to be an ...
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report), ...
Dr Reddy's expects overall sales to grow in double digits, with branded business in India and emerging markets growing in ...
The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.
Out of the 40 analysts that track Dr. Reddy's, 13 of them have a 'Buy' recommendation, while 16 of them have a 'Sell' call.
Motilal Oswal recommended Neutral rating on Dr Reddys Laboratories with a target price of Rs 1390 in its research report ...
Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.36% to 1,272.55 Indian rupees Tuesday, on what proved to be an ...
Dr Reddy's Labs reports 9.5 percent fall in consolidated net profit after tax to Rs 1342 crore in Q2
Indian generic drugmaker Dr Reddy's Laboratories recorded a 9.5 percent decline in its consolidated net profit after tax to ...
Dr. Reddy’s Laboratories Ltd ( (RDY)) has released its Q2 earnings. Here is a breakdown of the information Dr. Reddy’s Laboratories Ltd presented to its investors. Dr. Reddy’s Laboratories Ltd., a ...
For the July-September 2024 period, net profit is expected to decline by 3% year-on-year, based on the average estimate from ...
Dr Reddy's Laboratories Ltd. reported its Q2 FY25 results, with a notable revenue increase of 16.5%, reaching Rs 8,016.2 ...
Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback